Brief: Shanghai Henlius Biotech Enters License Agreement With Alvogen Korea
25/04/2025 10:50
April 25 (Reuters) - Shanghai Henlius Biotech Inc 2696.HK: ENTERS LICENSE AGREEMENT WITH ALVOGEN KOREA ALVOGEN KOREA GRANTED EXCLUSIVE RIGHTS FOR HANSIZHUANG IN SOUTH KOREA ALVOGEN KOREA TO PAY $5 MILLION UPFRONT, OTHERS Further company coverage: 2696.HK ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln